Metformin use and survival from lung cancer: A population-based cohort study.

  title={Metformin use and survival from lung cancer: A population-based cohort study.},
  author={{\'U}na C. Mc Menamin and Chris Cardwell and Carmel M. Hughes and Liam M. Murray},
  journal={Lung cancer},
Preclinical evidence suggests that metformin, a widely prescribed anti-diabetic drug, may inhibit lung cancer progression. We investigated whether metformin use was associated with decreased risk of cancer-specific mortality in lung cancer patients. This study included newly diagnosed lung cancer patients (identified from English National Cancer Data Repository, 1998-2009) with type 2 diabetes (based on UK Clinical Practice Research Datalink prescriptions and diagnosis records). Lung cancer… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 2 times. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.


Publications citing this paper.
Showing 1-7 of 7 extracted citations


Publications referenced by this paper.
Showing 1-10 of 19 references

Prognosis of small cell lung cancer patients with diabetes treated with metformin.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico • 2015
View 1 Excerpt

Statin use and survival from lung cancer: a population-based cohort study.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology • 2015
View 1 Excerpt

Survival of patients with stage IV lung cancer with diabetes treated with metformin.

American journal of respiratory and critical care medicine • 2015
View 3 Excerpts

Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2013
View 1 Excerpt

Similar Papers

Loading similar papers…